SBC trades 305.4% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SBC achieves its forward estimates and maintains a stable P/E multiple of 6.4x. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, SBC Medical Group Holdings Incorporated (SBC) has a Wall Street consensus price target of $12.00, based on estimates from 1 covering analysts. With the stock currently trading at $2.96, this represents a potential upside of +305.4%. The company has a market capitalization of $304M.
Analyst price targets range from a low of $9.00 to a high of $15.00, representing a 50% spread in expectations. The median target of $12.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SBC trades at a trailing P/E of 5.9x and forward P/E of 6.4x. Analysts expect EPS to grow +16.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $2.86, with bear and bull scenarios of $1.80 and $3.77 respectively. Model confidence stands at 35/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SKINThe Beauty Health Company | $144M | $1.11 | $1.53 | +37.8% | Hold | — | 14 |
INMDInMode Ltd. | $921M | $14.54 | $18.00 | +23.8% | Hold | 10.9x | 11 |
SSKNSTRATA Skin Sciences, Inc. | $705406 | $0.12 | — | — | — | — | — |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
LASELaser Photonics Corporation | $22M | $1.30 | — | — | — | — | — |
AEYEAudioEye, Inc. | $93M | $7.41 | — | — | — | — | — |
ISRGIntuitive Surgical, Inc. | $151.3B | $427.30 | $597.78 | +39.9% | Buy | 40.9x | 55 |
EWEdwards Lifesciences Corporation | $54.6B | $94.82 | $97.45 | +2.8% | Buy | 31.5x | 48 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
GMEDGlobus Medical, Inc. | $10.6B | $78.83 | $109.50 | +38.9% | Buy | 16.6x | 36 |
Quick answers to the most common questions about buying SBC stock.
The consensus Wall Street price target for SBC is $12, representing 305.4% upside from the current price of $2.96. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SBC has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 305.4% upside from current levels.
With a forward P/E of 6.4069x, SBC trades at a relatively low valuation. The consensus target of $12 implies 305.4% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $15 for SBC, while the most conservative target is $9. The consensus of $12 represents the median expectation. Our quantitative valuation model projects a bull case target of $4 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
SBC is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SBC stock forecast based on 1 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $9 (bear case) to $15 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $3, with bear/bull scenarios of $2/$4.
Our quantitative valuation model calculates SBC's fair value at $3 (base case), with a bear case of $2 and bull case of $4. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 35/100.
SBC trades at a forward P/E ratio of 6.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 5.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on SBC, with a "Buy" consensus rating and $12 price target (305.4% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SBC analyst price targets range from $9 to $15, a 50% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground. Our model's $2-$4 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.